The Japanese experience with metabolic imaging in the clinical setting

Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations

"Ischaemic memory" is defined as a prolonged functional and/or biochemical alteration remaining after a particular episode of severe myocardial ischaemia. The biochemical alteration has been reported as metabolic stunning. Metabolic imaging has been used to detect the footprint left by previous ischaemic episodes evident due to delayed recovery of myocardial metabolism (persistent dominant glucose utilization with suppression of fatty acid oxidation). β-Methyl-p-[(123)I]iodophenylpentadecanoic acid (BMIPP) is a single-photon emission computed tomography (SPECT) radiotracer widely used for metabolic imaging in clinical settings in Japan. In patients with suspected coronary artery disease but no previous myocardial infarction, BMIPP has shown acceptable diagnostic accuracy. In particular, BMIPP plays an important role in the identification of prior ischaemic insult in patients arriving at emergency departments with acute chest pain syndrome. Recent data also show the usefulness of (123)I-BMIPP SPECT for predicting cardiovascular events in patients undergoing haemodialysis. Similarly, SPECT or PET imaging with (18)F-FDG injected during peak exercise or after exercise under fasting conditions shows an increase in FDG uptake in postischaemic areas. This article will overview the roles of ischaemic memory imaging both under established indications and in ongoing investigations.

Role of imaging for acute chest pain syndromes

Acute chest pain suggestive of ischemic cardiac origin, with a normal or nondiagnostic electrocardiogram and negative initial cardiac markers for myocardial necrosis represent a significant diagnostic dilemma for clinicians. Multiple imaging modalities play a pivotal role in early diagnosis and safe discharge of these patients. In this review, we compare the current imaging modalities available for these patients including their diagnostic accuracy, feasibility, and cost effectiveness. Acute rest myocardial perfusion imaging significantly improves the clinical outcome in these patients and reduces the overall cost when incorporated into the decision making pathway. The choice of imaging modality recommended should be based on local institutional expertise and the overall clinical presentation. The imaging modality with high diagnostic accuracy and negative predictive value will provide for precise risk stratification which is important to clinical decision making, including patients who require admission to the hospital and those who can be safely discharged.

Myocardial perfusion scintigraphy: past, present and future

During the last two decades, radionuclide myocardial perfusion scintigraphy (MPS) has become established as the main functional cardiac imaging technique for the assessment of ischaemic heart disease (IHD). Despite a growing number of alternative functional imaging techniques, MPS still remains the most widely used technique, with a wealth of literature supporting its usefulness in assessing IHD and predicting prognosis. The technique itself has evolved, making it more reliable and robust, with additional ventricular functional information that further defines the prognosis in these patients. With the advent of hybrid single photon emission with CT and positron emission tomography with CT cameras together with the development of new camera technology that enables faster images with less radiation and better resolution, MPS will remain an essential part of IHD investigation. There are new promising radiopharmacological developments and applications such as radiolabelled fatty acids and meta-iodobenzylguanidine. These will widen the scope of nuclear medicine imaging to include patients with cardiac failure and acute chest pain presenting to accident and emergency departments. Nuclear medicine cardiac investigations will continue to have an essential role in the diagnosis, stratification and prognosis of patients with cardiac disease, complementing the new developing cardiac modalities such as CT coronary angiography and MRI.

Validation of automated quantitation of myocardial perfusion and fatty acid metabolism abnormalities on SPECT images

BACKGROUND

Myocardial perfusion and fatty acid imaging have played important roles in the risk stratification of patients with coronary artery disease (CAD). However, visual image assessment requires considerable experience and training. Therefore, an automated program has been developed that can quantify perfusion and fatty acid uptake on myocardial single emission computed tomography (SPECT). The present study aimed to validate the automated quantitative program.

METHODS AND RESULTS

A total of 50 patients were studied with known or suspected CAD who underwent stress ²⁰¹Thallium (²⁰¹Tl) and resting ¹²³I-labelled β-methyl iodophenyl pentadecanoic acid (BMIPP) SPECT. The SPECT images were quantified in 17 segments visually and using our Heart Score View software. Values were compared with those in a normal Japanese database and calculated summed stress (SSS), summed rest (SRS), summed difference (SDS), and summed BMIPP scores for each modality. Summed scores obtained using standard visual analysis and Heart Score View significantly correlated (²⁰¹Tl: SSS: r=0.934; SRS: r=0.827; SDS: r=0.743 summed BMIPP score: r=0.913) (each P<0.001) and Bland-Altman analysis revealed good agreement between the 2 approaches.

CONCLUSIONS

Correlations between scores determined using Heart Score View software and standard visual interpretation were linear for both perfusion and fatty acid images. Thus, our new automated program might be useful for the risk stratification of patients with CAD in the clinical setting.

Accelerated BMIPP uptake immediately after reperfused ischemia in the isolated rat heart model

OBJECTIVE

123I-beta-methyl iodophenyl pentadecanoic acid (BMIPP) can visualize myocardial fatty acid metabolism and has extensive potential for diagnosing cardiac diseases such as acute coronary syndrome in the clinical setting. Increased BMIPP uptake with decreased perfusion occasionally occurs under acute reperfusion ischemia and the kinetics of BMIPP remain unclear. The present study uses the isolated rat heart model to measure kinetic changes in BMIPP under acute reperfusion ischemia.

METHODS

Male Wistar rats were allotted to normal control (NG), mild (MG) and severe (SG) ischemia groups. The hearts were perfused according to the Langendorff method at a constant flow rate, and BMIPP wash-in and wash-out were studied. No-flow ischemia was applied for 15 and 30 min to the MG and SG groups, followed immediately by the wash-in and wash-out study. Whole heart radioactivity was determined using an external gamma detector throughout the experiment. Rates of myocardial uptake (K1, mL/min) and clearance (k2, min(-1)) were generated using a compartmental model analysis. The same procedures and protocols were performed using (99m)Tc-sestamibi (MIBI) as a perfusion study.

RESULTS

Perfusion pressure significantly increased and mean heart rate significantly decreased in the severe ischemia group (heart rate: 244 ± 76, 304 ± 105 and 94 ± 140 bpm; perfusion pressure: 67 ± 13, 101 ± 31 and 160 ± 84 mmHg for NG, MG and SG, respectively). MIBI-K1 significantly decreased, whereas BMIPP-K1 increased in the MG and SG groups (MIBI-K1: 3.45 ± 1.10, 1.95 ± 0.82, and 1.05 ± 0.13 mL/min; BMIPP-K (1): 3.06 ± 0.88, 3.91 ± 0.87, and 4.94 ± 1.51 mL/min for NG, MG and SG, respectively) with an inverse relationship to the severity of ischemia. MIBI-k2 increased markedly in severe ischemia (NG vs. MG: p < 0.05), whereas BMIPP-k2 did not change in the ischemic groups (MIBI-k2: 0.00072 ± 0.0011, 0.00038 ± 0.00076 and 0.043 ± 0.033; BMIPP-k2: 0.0056 ± 0.0028, 0.0029 ± 0.0010 and 0.0037 ± 0.0022 min(-1) for NG, MG and SG, respectively).

CONCLUSION

Myocardial BMIPP uptake increased immediately upon reperfusion after no-flow ischemia, and was inversely related to the severity of ischemia. The increased uptake was not due to reduced clearance, but to accelerated extraction.

Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology

With the rapid growth of molecular biology, in vivo imaging of such molecular process (i.e., molecular imaging) has been well developed. The molecular imaging has been focused on justifying advanced treatments and for assessing the treatment effects. Most of molecular imaging has been developed using PET camera and suitable PET radiopharmaceuticals. However, this technique cannot be widely available and we need alternative approach. ¹²³I-labeled compounds have been also suitable for molecular imaging using single-photon computed tomography (SPECT) ¹²³I-labeled meta-iodobenzylguanidine (MIBG) has been used for assessing severity of heart failure and prognosis. In addition, it has a potential role to predict fatal arrhythmia, particularly for those who had and are planned to receive implantable cardioverter-defibrillator treatment. ¹²³I-beta-methyl-iodophenylpentadecanoic acid (BMIPP) plays an important role for identifying ischemia at rest, based on the unique capability to represent persistent metabolic alteration after recovery of ischemia, so called ischemic memory. Since BMIPP abnormalities may represent severe ischemia or jeopardized myocardium, it may permit risk analysis in CAD patients, particularly for those with chronic kidney disease and/or hemodialysis patients. This review will discuss about recent development of these important iodinated compounds.